Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 3OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Neuroblastoma 4Melanoma 4Lymphoma 4Hodgkin Disease 4Uveal Melanoma 2Sarcoma 2Recurrence 2Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1HIV Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

montanide ISA 51 3Temozolomide 3Ipilimumab 3Interleukin-2 3sargramostim 2incomplete Freund's adjuvant 2glembatumumab vedotin 2aldesleukin 2Vorinostat 2Sunitinib 2Paclitaxel 2MART-1 Antigen 2Lenalidomide 2Dacarbazine 2Cyclophosphamide 2Carboplatin 2CR011-vcMMAE 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1poly ICLC 1omipalisib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1entinostat 1cixutumumab 1cediranib 1cabozantinib 1aflibercept 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Uveal Melanoma × Dacarbazine × Clear all
NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled 8 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡